Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 71Active not recruiting 8Unknown 6Terminated 6Recruiting 5Not yet recruiting 3Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1

Conditions

Pain, Intractable 1Neoplasms 1Neoplasm, Residual 1Nausea 1Leukemia, Myeloid, Acute 1Dyspnea 1Delirium 1Death 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Midazolam × Clear all
NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Novartis

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT01687751 2015-05-25

Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients

Fraser Health

Phase 2 Withdrawn
Other

Death, Delirium, Dyspnea, Nausea, Neoplasms, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡